

CONTENTS

Special Issue: Second International Conference on Lipoprotein[a], November 12-14, 1992

A.M. Gotto, Jr. (Houston, TX), <i>The Second International Conference on Lipoprotein[a]: Preface</i>	1
K. Berg (Oslo, Norway), <i>Lp(a) lipoprotein: an overview</i>	9

Session I: Structure of Apo[a]

R.M. Lawn (Stanford, CA), <i>The apolipoprotein(a) gene: characterization of 5' flanking regions and expression in transgenic mice</i>	19
M. Pursiainen, M. Jauhiainen, P.T. Kovanen, C. Ehnholm (Helsinki, Finland), <i>Proteolytic degradation of low-density lipoprotein by lipoprotein(a) and by recombinant Apo(a)</i>	25
F. Blanco-Vaca, J.W. Gaubatz, N. Bren, B.A. Kottke, J.D. Morrisett, J. Guevara, Jr. (Houston, TX; Rochester, MN), <i>Identification and quantification of apolipoproteins in addition to apo[a] and apo B-100 in human lipoprotein[a]</i>	35
M. Cox, J. Schaller, R. Boelens, R. Kaptein, E. Rickli, M. Llinás (Utrecht, The Netherlands; Berne, Switzerland; Pittsburgh, PA), <i>Kringle solution structures via NMR: two-dimensional ¹H-NMR analysis of horse plasminogen kringle 4</i>	43
R.K. Arni, K. Padmanabhan, K.P. Padmanabhan, T.-P. Wu, A. Tulinsky (East Lansing, MI), <i>Structure of the non-covalent complex of prothrombin kringle 2 with PPACK-thrombin</i>	59

Session II: Structure of Lp[a]

G.M. Fless, M.L. Snyder (Chicago, IL), <i>Polymorphic forms of Lp(a) with different structural and functional properties: cold-induced self-association and binding to fibrin and lysine-sepharose</i>	69
J. Sines, R. Rothnagel, M. van Heel, J.W. Gaubatz, J.D. Morrisett, W. Chiu (Houston, TX; Berlin, Germany), <i>Electron cryomicroscopy and digital image processing of lipoprotein(a)</i>	81
M.L. Phillips, A.V. Lumbert, V.N. Schumaker, R.M. Lawn, S.J. Shire, T.F. Zionscheck (Los Angeles, Stanford, South San Francisco, CA), <i>Electron-microscopic and hydrodynamic characterization of recombinant apolipoprotein(a) and its association with LDL</i>	91
C.-Y. Yang, Z.-W. Gu, M. Yang, A.M. Gotto, Jr. (Houston, TX), <i>Primary structure of ApoB-100</i>	99
W.J. McConathy, V.N. Trieu, E. Koren, C.-S. Wang, C.C. Corder (Fort Worth, TX; Gaithersburg, MD; Oklahoma City, OK), <i>Triglyceride-rich lipoprotein interactions with Lp(a)</i>	105
A. Hermetter, A. Sommer, R. Gorges, E. Prenner, G.M. Kostner, F. Paltauf (Graz, Austria), <i>Apoprotein-phospholipid interactions in Lp(a)</i>	115

Session III: Cellular metabolism of Lp[a]

A.L. White, D.L. Rainwater, J.E. Hixson, L.E. Estlack, R.E. Lanford (San Antonio, TX), <i>Intracellular processing of apo(a) in primary baboon hepatocytes</i>	123
C. Edelstein, N.O. Davidson, A.M. Scanu (Chicago, IL), <i>Oleate stimulates the formation of triglyceride-rich particles containing ApoB100-Apo(a) in long-term primary cultures of human hepatocytes</i>	135
M.P. Mims, J.W. Gaubatz, K.K. Ghazzaly, D.P. Via, D.S. Clough, J.D. Morrisett (Houston, TX), <i>Interaction of LDL and Lp[a] with human skin fibroblasts</i>	145
G.M. Kostner, H. Grillhofer (Graz, Austria), <i>The interaction of Lp(a) with normal and LDL-receptor-deficient human skin fibroblasts</i>	153
V.V. Tertov, A.N. Orekhov (Moscow, Russia), <i>Effect of lipoprotein(a) on lipid metabolism of cultured human intimal aortic cells</i>	161
M. Naruszewicz, L.-M. Giroux, J. Davignon (Montreal, Quebec), <i>Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a)</i>	167
J. Kreuzer, M.B. Lloyd, D. Bok, G.M. Fless, A.M. Scanu, A.J. Lusis, M.E. Haberland (Los Angeles, CA; Chicago, IL), <i>Lipoprotein(a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall</i>	175

Session IV: Metabolism of Lp[a] in vivo

A.M. Scanu, D. Pfaffinger, C. Edelstein (Chicago, IL), <i>Post-prandial Lp(a): identification of a triglyceride-rich particle containing apo E</i>	193
D.L. Rainwater (San Antonio, TX), <i>Genetic effects on dietary response of Lp(a) concentrations in baboons</i>	199
G.C. Cardoso, C. Posadas, O.O. Orvanaños, C. Peniche, J. Zamora, R. Aguilar, J.A. Holguin, A.S. Raynaud, J.D. Morrisett, J. Guevara, Jr. (Mexico City, Mexico; Houston, TX), <i>Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a)</i>	207
S.M. Haffner, M. Frangos, J. Williamson, J. Santiago, R. Valdez, G. Aldrete, L. Mykkänen, K.K. Gruber, D.L. Rainwater (San Antonio, TX; St. Louis, MO), <i>Lp(a) concentrations and phenotypes in children with insulin-dependent diabetes mellitus</i>	223
B.L. Knight (London, UK), <i>Lp(a) catabolism in hypercholesterolaemic individuals</i>	233

Session V: Quantification of Lp[a]

D.C. Usher, C. Swanson, D.J. Rader, J. Krämer, H.B. Brewer (Newark, DE; Bethesda, MD), <i>A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies</i>	243
B.A. Kottke, N.D. Bren (Rochester, MN), <i>A particle concentration fluorescence immunoassay for Lp(a)</i>	249
J.J. Albers, S.M. Marcovina (Seattle, WA), <i>Standardization of Lp(a) measurements</i>	257
C. Labeur, M. Rosseneu, O. Henderson (Ghent, Brugge, Belgium; Atlanta, GA), <i>International Lp(a) standardization</i>	265
H.F. Hoff, J. O'Neil, G.B. Smejkal, A. Yashiro (Cleveland, OH), <i>Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions</i>	271

Session VI: Lp[a] Population studies

M.I. Kamboh, C.M. Svitko, E.R. Williams, R.E. Ferrell, W.S. Pollitzer (Pittsburgh, PA; Columbia, SC; Chapel Hill, NC), <i>Hypervariable polymorphism of Apo(a) in blacks and whites as reflected by phenotyping</i>	283
Z. Yiyi, L. Janjun, W. Junjun (Nanjing, China), <i>Apolipoprotein(a) phenotypes in cardio-cerebrovascular diseases</i>	293
D.E.L. Wilcken, X.L. Wang, N.P.B. Dudman (Sydney, Australia), <i>The relationship between infant and parent Lp(a) levels</i>	299
G. Ghiselli, A. Gaddi (Houston, TX; Bologna, Italy), <i>The relation of LDL receptor activity to lipoprotein(a) plasma concentration in patients without coronary artery disease</i>	305

Session VII: Therapeutic interventions for lowering Lp[a] levels

V.W. Armstrong, P. Schuff-Werner, T. Eisenhauer, M. Helmhold, M. Stix, D. Seidel (Goettingen, München, Germany), <i>Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels</i>	315
S.N. Pokrovsky, A.V. Sussekov, O.I. Afanasieva, I.Y. Adamova, A.A. Lyakishev, V.V. Kukharchuk (Moscow, Russia), <i>Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data</i>	323
T.S. Parker (New York, NY), <i>Dextran-sulfate cellulose adsorption for lowering Lp[a]</i>	331
S. Kanemitsu, N. Tekekoshi, E. Murakami (Ishikawa, Japan), <i>Effects of LDL apheresis on restenosis after angioplasty</i>	339
M.R. Soma, M. Meschia, F. Bruschi, J.D. Morrisett, R. Paoletti, R. Fumagalli, P. Crosignani (Milan, Italy; Houston, TX), <i>Hormonal agents used in lowering lipoprotein(a)</i>	345

Session VIII: Role of Lp[a] in thrombosis and fibrinolysis

E. Anglés-Cano (Bicêtre, France), <i>Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces</i>	353
J. Edelberg, S.V. Pizzo (Durham, NC), <i>Lipoprotein(a) regulates plasmin generation and inhibition</i>	363
E. Anglés-Cano, L. Hervio, D. Rouy, C. Fournier, J.M. Chapman, M. Laplaud, M.L. Koschinsky (Bicêtre, Paris, France; Kingston, Canada), <i>Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator</i>	369
E. von Hodenberg, E. Pestel, J. Kreuzer, M. Freitag, C. Bode (Heidelberg, Germany), <i>Effects of lipoprotein(a) on thrombolysis</i>	381

Session IX: Lp[a] in cardiovascular and cerebrovascular disease

C.R. Rodriguez, L.J. Seman, J.M. Ordovas, J. Jenner, M.S.J. Genest, Jr., P.W.F. Wilson, E.J. Schaefer (Boston, Framingham, MA), <i>Lipoprotein(a) and coronary heart disease</i>	389
H. Yamaguchi, Y.J. Lee, H. Daida, H. Yokoi, H. Miyano, T. Kanoh, S. Ishiwata, K. Kato, H. Nishikawa, F. Takatsu, Y. Kutsumi, H. Mokuno, N. Yamada, A. Noma (Tokyo, Japan), <i>Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART)</i>	399
P.J. Schreiner (Chapel Hill, NC), <i>Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort: the Atherosclerosis Risk in Communities (ARIC) Study</i>	405
A. Noma, A. Abe, S. Maeda, M. Seishima, K. Makino, Y. Yano, K. Shimokawa (Gifu, Japan), <i>Lp(a): an acute-phase reactant?</i>	411
M.D. Cressman, D. Abood, J. O'Neil, H.F. Hoff (Cleveland, OH), <i>Lp(a) and premature mortality during chronic hemodialysis treatment</i>	419
G. Jürgens, P. Költringer (Graz, Austria), <i>Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries</i>	429
Subject Index — Volumes 67/68	435
Author Index — Volumes 67/68	441
